Nanotechnological approaches in the treatment of schistosomiasis: an overview

• Lucas Carvalho,
• Michelle Sarcinelli and
• Beatriz Patrício

Beilstein J. Nanotechnol. 2024, 15, 13–25, doi:10.3762/bjnano.15.2

• ; nanoformulation; nanotechnology; neglected diseases; praziquantel; schistosoma; Introduction Schistosomiasis is a disease common in tropical countries caused by trematodes from the genus Schistosoma. More than 220 million people are affected by this disease, in addition to 800 million at risk of infection [1][2

Green SPIONs as a novel highly selective treatment for leishmaniasis: an in vitro study against Leishmania amazonensis intracellular amastigotes

• Brunno R. F. Verçoza,
• Robson R. Bernardo,
• Luiz Augusto S. de Oliveira and
• Juliany C. F. Rodrigues

Beilstein J. Nanotechnol. 2023, 14, 893–903, doi:10.3762/bjnano.14.73

• ; Introduction Leishmaniasis is one of the most important neglected diseases of chronic nature and remains a serious global health problem. A worrying increase has been observed in the number of leishmaniasis cases worldwide in recent decades. It is estimated that about 600 million people live in risk areas, and

A review on nanostructured silver as a basic ingredient in medicine: physicochemical parameters and characterization

• Gabriel M. Misirli,
• Kishore Sridharan and
• Shirley M. P. Abrantes

Beilstein J. Nanotechnol. 2021, 12, 440–461, doi:10.3762/bjnano.12.36

• used in the future against the increase of multidrug-resistant pathogenic strains. In addition, AgNPs can also be used to combat neglected diseases such as dengue, leishmaniasis, malaria, schistosomiasis, and trypanosomiasis (Chagas disease) among other applications [5][19][24]. The unprecedented

• treatments, increasing the effectiveness of drug administration and producing antitumor effects [27][81]. In addition, AgNPs have a central role in the development of new treatments for neglected diseases, which are caused by infectious agents or parasites and are considered endemic in populations at low

• -income regions. Little is invested in the research and development of new drugs by the pharmaceutical industry to treat these neglected diseases as it is not commercially interesting [84][85]. AgNPs have appeared as a possible alternative in the therapy against many of these diseases as they present low